Ovid Therapeutics (OVID) Financials

Ovid Therapeutics’ Q2 2026 statements show a well-funded but still loss-making biotechnology company. The company reported $733,000 of revenue, reversing the zero revenue recorded in Q1 2026. However, revenue remains far below the $6.3 million reported in Q2 2025. Gross profit equaled revenue because reported cost of revenue was zero.

Operating expenses improved sequentially to $16.4 million from $17.8 million in Q1. Selling, general and administrative expense declined modestly to $6.5 million, while research and development expense fell to $10.0 million. Despite the improvement, Ovid posted a $15.0 million net loss and remained dependent on investment income and external financing.

The balance sheet remains relatively strong compared with the company’s operating needs. Ovid had $11.3 million of cash and equivalents and $105.9 million of short-term investments at June 30, 2026. Including $52.6 million of long-term investments, total investment assets were approximately $171.7 million. Total liabilities were only $22.1 million against $209.9 million of shareholders’ equity. However, cash and short-term investments declined from $155.5 million at the end of Q1, primarily because the company purchased $102.7 million of investments during the quarter.

• Significant liquidity: Cash, short-term investments and long-term investments totaled approximately $171.7 million at the end of Q2 2026, providing a substantial financial cushion relative to quarterly operating cash burn.
• Low leverage: Total liabilities of $22.1 million were modest compared with $231.97 million of total assets and $209.9 million of equity. The balance sheet does not show a meaningful traditional debt burden.
• Sequential expense improvement: Total operating expenses declined 13.5% from Q1 2026, with both SG&A and research and development spending lower than the prior quarter.
• Revenue returned in Q2: Ovid generated $733,000 of revenue after reporting no revenue in Q1 2026, although investors should determine whether this represents a sustainable commercial trend.
• Investment portfolio management is driving cash movements: Ovid made substantial investment purchases while also receiving proceeds from investment sales and maturities. This makes changes in cash and equivalents less representative of operating performance alone.
• Potential funding runway: Q2 operating cash outflow was $17.6 million. Based on liquid investments alone, the company appears to have several quarters of funding capacity, but the actual runway will depend on development spending, investment activity, revenue and future financing.
• Persistent operating losses: Ovid has reported operating losses in every quarter shown. The Q2 2026 operating loss was $15.7 million, and the company’s $733,000 of revenue covered only a small portion of operating expenses.
• Continued cash burn: Net cash used in operating activities increased to $17.6 million in Q2 from $13.9 million in Q1. The company’s operations are not yet self-funding.
• Heavy reliance on financing: Q2 financing activities provided $21.6 million, while Q1 financing provided $89.0 million. Without financing proceeds or investment income, operating and investing cash outflows would continue to reduce liquidity.
• Substantial share-count growth and dilution risk: Weighted average basic shares outstanding increased to 197.5 million in Q2 2026 from 136.2 million in Q1 and approximately 71.1 million in Q2 2025. The increase indicates that equity financing and other share activity have materially expanded the share base, potentially reducing existing shareholders’ ownership and per-share value.

Overall, Ovid’s financial position is supported by a large investment portfolio and limited liabilities, but the company continues to consume cash and report operating losses. The key issues for investors are whether revenue can grow beyond occasional or partnership-related receipts, whether research spending can produce successful products, and how much additional equity financing may be required.